<DOC>
	<DOCNO>NCT00807001</DOCNO>
	<brief_summary>This proof-of-concept study provide data safety antiviral activity several dos investigational drug IDX184 give 3 day treatment-naive HCV genotype 1-infected subject optimal dos choose test late study .</brief_summary>
	<brief_title>Double-Blind , Dose-Escalation Study IDX184 Chronic Hepatitis C Treatment-Naïve Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Inclusion criterion : 1 . 1865 year old 2 . Subject childbearing potential must agree use consistent form acceptable doublebarrier method birth control . 3 . Plasma HCV RNA ≥ 5 log10 IU/mL 4 . HCV genotype 1 Exclusion criterion : 1 . Received prior antiviral treatment hepatitis C infection 2 . Subject pregnant breastfeeding 3 . Body Mass Index ( BMI ) &gt; 32 4 . Currently abuse alcohol illicit drug 5 . Currently receive methadone , buprenorphine drug treatment opioid addiction 6 . Coinfected hepatitis B virus ( HBV , HBsAg positive ) and/or human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatitis C , HCV , treatment-naive</keyword>
</DOC>